文献速递肝病消化道肿瘤与早癌

乙型肝炎病毒相关肝细胞癌预防中抗病毒治疗利用不足的相关因素

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus-Related Hepatocellular Carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2025-06-07

该研究分析台湾大型医疗集团2004年4月1日至2022年5月24日期间1017例乙型肝炎病毒相关肝细胞癌患者的电子病历,按肝癌诊断前是否接受抗病毒治疗分组。结果显示75%的患者在发生肝癌前未接受抗病毒治疗,未治疗组肝硬化比例更低、专科就诊次数更少、肝癌分期更晚且生存期更短。

要点

  • 1017例乙型肝炎病毒相关肝细胞癌患者中,75%在肝癌诊断前未接受抗病毒治疗。
  • 未治疗组专科就诊频率中位数为每年0.3次,治疗组为每年3.6次。
  • 未治疗组早期(I/II期)诊断比例为49.5%,治疗组为81.6%。

核心结论

  • 四分之三的乙型肝炎病毒相关肝细胞癌患者在肝癌诊断前未接受抗病毒治疗,这些患者以肝硬化比例较低、临床就诊不频繁、乙型肝炎病毒评估较少、肝癌分期更晚和预后更差为特征。

研究设计与样本

  • 分析台湾一家大型医疗集团2004年4月1日至2022年5月24日期间的电子病历,纳入所有发生肝细胞癌的乙型肝炎病毒感染患者,乙型肝炎病毒感染经乙型肝炎表面抗原血清阳性确认,新发肝细胞癌经癌症登记处核实。

主要发现

  • 共纳入1017例乙型肝炎病毒相关肝细胞癌患者,中位年龄60.8岁,男性占80.1%,肝硬化占42.9%。
  • 75%的患者在发生肝细胞癌前未接受抗病毒治疗。
  • 与治疗组相比,未治疗组肝硬化比例显著更低(33.5% vs. 71.0%),血小板计数更高,肝酶水平升高,病毒载量更高。
  • 未治疗组专科就诊次数显著更少(中位频率每年0.3次 vs. 3.6次),生物标志物评估更少,早期(I/II期)诊断比例更低(49.5% vs. 81.6%),中位生存期显著更短(2.1年 vs. 4.4年)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Deaths from hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) are projected to increase through 2030. Underutilisation of antiviral therapy may contribute to this concerning trend but empirical data remain sparse. AIMS: We aimed to assess the frequency of missed opportunities for antiviral therapy before HBV-related HCC development and to investigate factors associated with non-treatment. METHODS: We analysed the electronic medical records from a large healthcare group in Taiwan to identify all HBV-infected patients who developed HCC between 1 April 2004 and 24 May 2022. HBV infection was confirmed by hepatitis B surface antigen seropositivity and incident HCC was verified through the cancer registry. Patients were grouped based on whether they had received antiviral therapy prior to the HCC diagnosis. RESULTS: Among 1017 patients with HBV-related HCC (median age, 60.8 years; 80.1% male; 42.9% with cirrhosis), 75% had not received antiviral therapy before developing HCC. Compared to treated patients, the untreated group had a significantly lower proportion of cirrhosis (33.5% vs. 71.0%), higher platelet counts, elevated liver enzyme levels, and higher viral loads. They also had significantly fewer specialist visits (median frequency, 0.3 vs. 3.6 visits per year) and biomarker evaluations, and were less frequently diagnosed at early stages (Stage I/II, 49.5% vs. 81.6%) with a significantly shorter median survival (2.1 vs. 4.4 years). CONCLUSION: Three-quarters of patients who developed HBV-related HCC had not received antiviral therapy before HCC diagnosis. These patients were characterised by a lower proportion of cirrhosis, infrequent clinical visits, fewer HBV evaluations, more advanced HCC stage, and poorer prognosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wu JL, Tsai YN, Tseng CH, et al. Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus-Related Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2025. PMID: 40481816. doi:10.1111/apt.70224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。